14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBG vs IBO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBG carries a Unified Composite Score of 45.2/100 (HOLD) at $0.75 (N/M Forward P/E, -187.6% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin).
Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY).
Technical & Structure Timing Caution: IBG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBG vs IBO. Trailing 12-month operating profitability (IBG -187.6% vs IBO -12621.0%) and valuation multiples (IBG N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Beverages - Wineries & Distilleries value chain with $3.3M market capitalization and -187.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
IBO Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IBG vs IBO Key Questions & Quantitative Answers
As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Innovation Beverage Group Limited (IBG) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). IBG carries a Unified Composite Score of 45.2/100 (HOLD) at $0.75 (N/M Forward P/E, -187.6% operating margin), whereas IBO carries 36.8/100 (SELL) at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While IBG currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (7–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. -187.6% operating margin) and revenue trajectory (+16.7% vs. -38.6% YoY). Technical & Structure Timing Caution: IBG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.5); meanwhile IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBO leads the Growth & Scale pillar: IBG posts -38.6% YoY revenue growth and +0.0% YoY earnings growth on $2.8M TTM revenue (44.2% gross margin, -187.6% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). On trailing 12-month operating scale, IBG generates $2.8M in USD-normalized revenue versus $2.6M for IBO. In operating R&D and SG&A reinvestment, IBG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.
IBG and IBO trade at balanced relative valuation multiples. IBG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported EBITDA margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBG (-159.3% ROE) versus IBO (71.2% ROE) capital efficiency.
In options market volatility and institutional positioning, IBG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 126% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.